f Endochondral ossification is a highly regulated process that relies on properly orchestrated cell-cell interactions in the developing growth plate. This study is focused on understanding the role of a crucial regulator of cell-cell interactions, the membrane-anchored metalloproteinase ADAM17, in endochondral ossification. ADAM17 releases growth factors, cytokines, and other membrane proteins from cells and is essential for epidermal growth factor receptor (EGFR) signaling and for processing tumor necrosis factor alpha. Here, we report that mice lacking ADAM17 in chondrocytes (A17⌬Ch) have a significantly expanded zone of hypertrophic chondrocytes in the growth plate and retarded growth of long bones. This abnormality is caused by an accumulation of the most terminally differentiated type of chondrocytes that produces a calcified matrix. Inactivation of ADAM17 in osteoclasts or endothelial cells does not affect the zone of hypertrophic chondrocytes, suggesting that the main role of ADAM17 in the growth plate is in chondrocytes. This notion is further supported by in vitro experiments showing enhanced hypertrophic differentiation of primary chondrocytes lacking Adam17. The enlarged zone of hypertrophic chondrocytes in A17⌬Ch mice resembles that described in mice with mutant EGFR signaling or lack of its ligand transforming growth factor ␣ (TGF␣), suggesting that ADAM17 regulates terminal differentiation of chondrocytes during endochondral ossification by activating the TGF␣/EGFR signaling axis.
S
keletal development is crucial to ensure optimal mobility and breathing, as well as protection of vital organs, such as the brain, spinal cord, lung, and heart. The axial and appendicular skeletons are formed through the generation of a cartilage intermediate, a process known as endochondral ossification, whereas the skull and clavicles are formed through intramembranous ossification (1) (2) (3) . In the limb bud, which can be used as a model, endochondral ossification is initiated when mesenchymal precursor cells condense and the most central chondrocytes begin to differentiate. Eventually, this gives rise to different zones of chondrocytes in the growth plate, beginning with the resting zone, followed by the proliferating zone and the hypertrophic zone, in which chondrocytes secrete a type X collagen-rich matrix (1, 2) . Once the hypertrophic chondrocytes mature into a terminally differentiated state and the lowermost cell layer becomes surrounded by mineral, the hypertrophic chondrocytes undergo apoptosis. This area in the developing long bone is directly adjacent to the primary center of ossification and is remodeled into trabecular bone as the invading vasculature supports the influx of osteoblasts and osteoclasts. In this process, the calcified matrix laid down by the hypertrophic chondrocytes is thought to be degraded through proteolytic activities, including MMP13 and MMP9 (4) , while the remaining matrix provides a scaffold for the formation of trabecular bone. A secondary center of ossification develops after birth in mice at both ends of developing long bones.
One of the signaling pathways that regulates endochondral ossification and differentiation of hypertrophic chondrocytes involves activation of the epidermal growth factor receptor (EGFR), a tyrosine kinase receptor with important roles in development and disease (3, 5) . Mice carrying the human EGFR instead of the mouse receptor have an enlarged zone of hypertrophic cells, presumably because the human EGFR is only weakly expressed, thereby generating a partial loss-of-function mutation (6) . An analysis of Egfr Ϫ/Ϫ mice revealed an expanded hypertrophic zone as well as a lack of osteoclast recruitment (7) . Moreover, treatment of 1-month-old rats with the EGFR inhibitor gefitinib results in a profound expansion of the growth plate, caused by an increased size of the hypertrophic zone (8) . This treatment reduces the MMP9, MMP13, and MMP14 levels at the chondro-osseus junction (COJ) and causes a defect in osteoclast migration to the COJ, presumably due to altered levels of RANKL and OPG released by hypertrophic chondrocytes (8) . An expansion of the hypertrophic zone was also seen in mice carrying a dominant-negative allele of Egfr (Wa5), and this was exacerbated by inactivation of the other, floxed allele of Egfr by the chondrocyte-specific Col2a1-Cre (8) . Taken together, these results demonstrate that chondrocyte growth or differentiation is regulated by the EGFR (8) .
The EGFR signaling pathway is activated by the binding of any of the seven EGFR ligands to the EGFR. All EGFR ligands are synthesized with a transmembrane domain and must be proteolytically released to create the active soluble growth factor (9, 10) . The membrane-anchored metalloproteinase ADAM17 (a disintegrin and metalloproteinase 17) has emerged as the principal sheddase for five EGFR ligands: heparin binding-epidermal growth factor (HB-EGF), transforming growth factor ␣ (TGF␣), amphiregulin, epiregulin, and epigen (11, 12) . The related ADAM10 is required for shedding of the remaining two ligands, betacellulin and EGF (12, 13) . Mice lacking ADAM17 resemble mice lacking the EGFR or specific EGFR ligands, in that they have open eyes at birth and wavy and stunted hair, as well as defects in lung and heart development (14) (15) (16) (17) (18) (19) . Moreover, targeted deletion of Adam17 in keratinocytes gives rise to skin barrier defects that resemble those observed in mice lacking the EGFR in keratinocytes (20, 21) . Mice with strongly reduced overall ADAM17 activity develop skin defects and intestinal inflammation that most likely are caused by a lack of TGF␣/EGFR signaling (22) . Interestingly, TGF␣ also appears to be the physiologically relevant EGFR ligand in endochondral ossification, as Tgf␣ Ϫ/Ϫ mice display a phenotype remarkably similar to that of EGFR inhibitor-treated rats (23) . These mice have an increased zone of hypertrophic chondrocytes with decreased levels of MMP13 and RANKL, resulting in reduced numbers of osteoclasts at the COJ at postnatal day 21 (P21). Taken together, these findings raise interesting questions about the role of ADAM17 as a regulator of cellcell interactions during bone development.
The role of ADAM17 in early endochondral ossification was first addressed by Boissy et al., who identified a defect of osteoclast migration into the primary center of ossification in Adam17 Ϫ/Ϫ mice (24) . Additionally, conditional deletion of ADAM17 in all osteochondroprogenitor cells (Adam17 flox/flox /Sox-9cre) results in an elongated hypertrophic zone as well as shorter proliferating zones (25) . The goal of this study was to gain a better understanding of the role of ADAM17 in endochondral ossification by analyzing Adam17 Ϫ/Ϫ mice in parallel with mice bearing conditional inactivation of Adam17 in chondrocytes, osteoclasts, or endothelial cells in different stages of development, as well as in adults.
MATERIALS AND METHODS

Ethics statement.
All experiments were performed according to the guidelines of the American Veterinary Association and were approved by the IACUC of the Hospital for Special Surgery.
Reagents and antibodies. All reagents were purchased from SigmaAldrich unless specified otherwise. ADAM17 was detected using a previously described antibody directed against its cytoplasmic domain (26). Cleaved collagen I or collagen II was detected using the C1,2C antibody (IBEX) against the shorter end of the cleavage site that generates the 3/4 and 1/4 fragments. Endomucin was detected using a purified anti-mouse endomucin antibody (eBiosciences).
Mouse strains. Mice with a transgene expressing the Cre recombinase under the control of the chondrocyte-specific Col2a1 promoter (27) , kindly provided by Hicham Drissi (University of Connecticut, Farmington, CT), were crossed with Adam17 flox/flox (28) mice to generate Adam17 flox/flox /Col2a1-cre mice, which are referred to as A17⌬Ch mice. Additionally, Adam17 flox/flox /LysM-Cre mice (A17⌬MC) lacking ADAM17 in the myeloid/osteoclast lineage (28) were crossed with A17⌬Ch mice to generate Adam17 flox/flox /LysM-Cre/Col2a1-cre (A17⌬Ch/MC) mice. Adam17 flox/flox /Tie2-cre mice have been previously described and are referred to as A17⌬EC mice (29) . Genotyping was performed by standard PCR protocols as described previously (LysM-cre and Adam17 flox were described by Horiuchi et al. [28] ; Col2a1-cre was described by Jackson Laboratories). Adam17 flox/flox littermates were used as controls and are referred to as the wild type (wt), as they showed no phenotypic abnormality (28, 29) . Adam17 Ϫ/Ϫ pups were generated from matings of Adam17 ϩ/Ϫ mice and identified by their open-eye phenotype (later confirmed by genotyping), which is not observed in the wt or heterozygous littermates (15, 28) . Tnf␣ Ϫ/Ϫ mice were purchased from Jackson Laboratories (B6;129S-Tnf tm1Gkl / J). All mice were of 129Sv/C57BL/6 mixed genetic background, and all comparisons were between littermates.
Histological analysis. (i)
Whole-mount alcian blue and alizarin red staining. Alcian blue and alizarin red staining were performed using a modified version of McLeod's method on ethanol-fixed samples (30) . Cartilage was stained with alcian blue, followed by clearing of the skeleton with potassium hydroxide and staining of the bones with alizarin red.
(ii) Sample processing. Samples were fixed overnight at 4°C in 4% paraformaldehyde (PFA). PFA was removed and replaced with 10% EDTA in 0.1 M Tris buffer, pH 7.4, for decalcification. Samples were decalcified for 6 to 14 days depending on the age of the pups. Samples were rinsed in running, distilled water for at least 4 h before dehydration and embedded in paraffin through immersion in a graded series of alcohol, xylene, and paraffin. Six-micrometer sections were floated in a 48°C water bath onto Superfrost Plus microscope slides (Cardinal Health). Slides were dried at 37°C overnight before further treatment.
(iii) Histological staining. Hematoxylin and eosin (H&E), safranin O, and fast green staining were performed according to standard protocols on paraffin-embedded sections. Von Kossa staining was performed on P0.5 samples that were fixed and washed 3 times with PBS without decalcification and then processed as described above. The sections were deparaffinized, rehydrated, and rinsed with water before immersion in a solution of 1% silver nitrate and exposed to UV light for 5 min in a Bio-Rad UV transilluminator. Residual silver was removed with one wash of 5% sodium thiosulfate. The samples were then counterstained with eosin.
(iv) TRAP staining. Tartrate-resistant acid phosphatase (TRAP) staining was performed on deparaffinized and rehydrated sections using an acid phosphatase, leukocyte TRAP kit (Sigma-Aldrich) according to the manufacturer's instructions.
(v) TUNEL staining. Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) staining was performed using an in situ cell death detection kit, fluorescein (Roche Applied Science) according to the manufacturer's directions. Staining was quantitated by counting all positively stained nuclei within an area of 100 m above and below the COJ (for a total width of 200 m) along the length of the COJ. This number was divided by the length of the COJ in m and multiplied by 100 to calculate the number of apoptotic specks per 100 m of COJ.
(vi) EdU labeling. The nucleotide 5-ethynyl-2=-deoxyuridine (EdU) was used to measure proliferation in a manner similar to that of bromodeoxyuridine (BrdU) incorporation. Pregnant mice were injected with EdU (10 g/g) and sacrificed 2 h postinjection. Embryos were fixed with 4% PFA and processed as described above. EdU detection was performed using a Click-iTEdU imaging kit (Invitrogen) according to the manufacturer's instructions. EdU-positive cells were marked by an Alexa Fluor 594 azide, imaged using a Nikon Eclipse E600 microscope, photographed using a Retiga Exi camera, and processed with the accompanying software from QImaging. All nuclei were stained with Hoechst dye and visualized under UV light. Images were imported into ImageJ (NIH), and EdUstained images (red) were merged with images of Hoechst staining (blue). All of the cells within a column closest to the middle of the section (width, 100 m; length, 700 m) were counted using the cell count function, and then cells with purple nuclei (EdU plus Hoechst stain) were counted separately. The cell proliferation ratio was calculated by dividing the number of EdU-stained cells by the total number of cell nuclei.
Immunohistochemistry. (i) Endomucin. After deparaffination and rehydration, samples were blocked in 2% bovine serum albumin (BSA) dissolved in phosphate-buffered saline (PBS). Anti-mouse endomucin (clone eBioV.7C7) (eBiosciences) was diluted 1:100 in 2% BSA-PBS and incubated with the samples overnight at 4°C. The samples were washed 3 times with PBS and incubated for 1 h at room temperature with anti-rat Cy3 (1:400) (Jackson ImmunoResearch). Samples were counterstained with Hoechst dye. After washing an additional 3 times with PBS, the samples were mounted in fluorescent mounting media (Dako) and processed as described above. Quantification was performed on a randomly selected area of 500 m along the COJ that started at the COJ and extended 100 m toward the trabecular side of the COJ for the P0.5 samples. For P21 samples, an area of 1,500 m along the COJ was chosen that extended into the trabecular side by 500 m. Positive pixels were selected using the magic wand tool set to recognize a value of red of 90 with a tolerance of 45, allowing positive pixels plus those with levels of Ϯ45 for red. The positive pixels were divided by the total number of pixels in the selected area in order to obtain the percent positive staining.
(ii) Collagen II (C1,2C) staining. After deparaffinization and rehydration, antigen retrieval was performed by incubating with hyaluronidase (Sigma-Aldrich) for 30 min at 37°C. Endogenous peroxidase activity was quenched using a 3% hydrogen peroxide solution. For blocking, secondary antibody, and signal amplification, the Vectastain ABC rabbit IgG kit (Vector Laboratories) was used according to the manufacturer's instructions. Primary antibody (C1,2C; IBEX) was used diluted 1:100. Signal was developed using NovaRED (Vector Laboratories).
(iii) In situ hybridization. Samples were dissected in diethyl pyrocarbonate (DEPC)-treated PBS and fixed overnight at 4°C in neutral buffered formalin (NBF). The samples were decalcified in a 50:50 mixture of NBF and 0.5 M EDTA for 7 days, washed 6 times with excess DEPC-treated water, paraffin embedded, and sectioned as described above, utilizing DEPC-treated water to prepare all reagents. Digoxigenin (DIG)-labeled probes were prepared using linearized DNA and a DIG RNA labeling kit (SP6/T7) (Roche) according to the manufacturer's instructions. Hybridization was performed as previously described (31) . For in situ hybridization using radioactive 35 S-labeled RNA probes, the procedures described by Gagnon et al. (32) were employed on humeri from P0.5 mice. The probes for in situ detection of Col10a1 mRNA (33) (originally generated in the laboratory of Kathryn Cheah, University of Hong Kong, Hong Kong), Runx2 mRNA (originally generated by the laboratory of Gerard Karsenty, Columbia University Medical Center, New York, NY), Mmp13 mRNA (2), and Col2a1 mRNA were obtained from D. Plumb (34) .
Faxitron analysis. Digital Faxitron images of disarticulated limbs were generated. The images were imported and the lengths of the bones measured in ImageJ. The longest distances from the proximal to the distal joint of tibiae and femurs were measured for this purpose.
CT analysis. P21 disarticulated tibiae were separated from all soft tissues before being fixed in 100% ethanol and then moved to 70% ethanol for analysis. The metaphysis and a section of the cortical bone of the tibiae were subjected to bone microcomputed tomography (microCT) analysis on a Scanco mCT 35 (Scanco Medical, Brüttisellen, Switzerland) system with a voxel size of 6 m. The images were analyzed by three-dimensional reconstruction using Scanco CT software (HP DECwindows Motif 1.6) with a global threshold of 0.4 g/mm 3 . Parameters were calculated as described by Bouxsein et al. (35) .
FTIR spectroscopic imaging. Distal humeri from wt and Adam17
Ϫ/Ϫ mice at embryonic day 18.5 (E18.5) were cleaned of soft tissue, embedded in polymethyl methacrylate, and sectioned at a 2-m thickness prior to examination by Fourier transform infrared (FTIR) imaging spectroscopy as detailed elsewhere (36) . Three sections from each bone, including the growth plate, primary spongiosa, and a section of long bone, were analyzed for mineral content, crystallinity, and collagen maturity. The distributions of these parameters in the images were visually compared, and the mean values of each parameter were compared. Western blot analysis. Primary cartilage isolated from P2 pups was lysed in 1% Triton X-100, 50 mM 1,10-phenanthroline (to prevent postlysis autodegradation of mature ADAM17 [26, 37] ), and 1ϫ protease inhibitor cocktail in PBS. Samples were homogenized using a Polytron (Polytron part 10-35 GT; Kinematica). After clearing the lysate by spinning at 15,000 ϫ g for 5 min to remove nuclei and cell debris, glycoproteins were concentrated on concanavalin A-Sepharose (25 l of 50% slurry per 1 ml of lysate; GE Healthcare). The bound glycoproteins were removed using SDS-sample loading buffer, reduced by the addition of 5 mM ␤-mercaptoethanol, and then separated on 10% SDS-PAGE gels and transferred to nitrocellulose. ADAM17 was detected using a previously described antibody directed against its cytoplasmic domain (26). Phosphorylated EGFR was detected using an anti-p-EGFR (Y1068) (D7A5) XP rabbit monoclonal antibody at 1:1,000 (Cell Signaling Technology).
ADAM9 was detected using a previously described antibody against the cytotail (38) .
Cell culture for in vitro differentiation. Primary mouse chondrocytes were isolated from 0.5-day-old wt and Adam17 Ϫ/Ϫ mouse articular cartilage by following a slightly modified version of a previous protocol for isolation of chondrocytes from P5 animals (39) . Passage 0 to 2 murine primary chondrocytes were plated at 2.5 ϫ 10 4 cells/cm 2 in Dulbecco's modified Eagle medium (DMEM)-F-12 containing 10% fetal bovine serum (FBS), 1ϫ ITS universal culture supplement (containing insulin, transferrin, and selenous acid; BD Biosciences), and 50 g/ml of ascorbic acid (Sigma-Aldrich) and were maintained in culture for the indicated times with medium changes every 48 h. For pellet cultures, 5 ϫ 10 5 wt or Adam17 Ϫ/Ϫ primary chondrocytes were pelleted in two sequential centrifugations (5 min at 4°C, 1000 ϫ g) and maintained in culture for 1 and 3 weeks in 500 ml of DMEM-F-12 containing 10% FBS, 1ϫ ITS, and 50 g/ml of ascorbic acid, with medium changes every 48 h. The hypertrophic differentiation and mineralization of chondrocytes was assessed by real-time quantitative reverse transcription-PCR (qRT-PCR) analysis and alizarin red staining (Sigma-Aldrich). Alizarin red staining was quantified by counting the number of positively staining nodules per well. The number of nodules seen in a wt well was set to one for each experiment and used to calculate the fold difference in the number of nodules generated by Adam17 Ϫ/Ϫ chondrocytes. Protein ectodomain shedding experiments with transfected alkaline phosphatase-tagged EGFR ligands were performed as described previously (12, 40) .
qRT-PCR analysis. For qRT-PCR analysis, total RNA was isolated from primary chondrocytes cultured in monolayers for 3 and 4 weeks after confluence or in pellet cultures for 3 weeks using standard protocols. Briefly, total RNA was isolated using TRIzol reagent (Life Technologies), and after DNase treatment (Qiagen) and column cleanup (Qiagen), 250 ng of total RNA was reverse transcribed using the QuantiTect reverse transcription kit (Qiagen) according to the manufacturer's instructions. Amplifications were carried out using SYBR green I-based RT-PCR on the Opticon 2 real-time PCR detector system (Bio-Rad) with the PCR primers listed below. Amplification efficiencies were calculated for all primers, utilizing serial dilutions of the pooled cDNA samples. The data were calculated as the ratio of each gene to expression of a housekeeping gene, Hprt, for monolayer culture and Gapdh for pellet culture, using the 2 Ϫ⌬⌬CT method for relative quantification. Data are represented as fold change versus the levels for the wt controls. Melting curves were generated to ensure a single gene-specific peak, and no-template controls were included for each run and each set of primers to control for unspecific amplifications. The following primers were used for qRT-PCR: mouse Col10a1, 5=-ACGCATCTCCCAGCACCAGAATC-3= (forward) and 5=-GGGGCTAGCAAGTGGGCCCT-3= (reverse); mouse Runx2, 5=-TCCCC GGGAACCAAGAAGGCA-3= (forward) and 5=-AGGGAGGGCCGTGG GTTCTG-3= (reverse); mouse Mmp13, 5=-ATGGTCCAGGCGATGAAG ACCCC-3= (forward) and 5=-GTGCAGGCGCCAGAAGAATCTGT-3= (reverse); mouse Vegfa, 5=-CTCGCAGTCCGAGCCGGAGA-3= (forward) and 5=-GCAGCCTGGGACCACTTGGC-3= (reverse); mouse Tnfsf11 (Rankl), 5=-CGAGCGCAGATGGATCCTAA-3= (forward) and 5=-CCCCCTGAAAGGCTTGTTTC-3= (reverse); mouse Tnfrsf11b (Opg), 5=-ACAGTTTGCCTGGGACCAAA-3= (forward) and 5=-TCACA GAGGTCAATGTCTTGGA-3= (reverse); mouse Hprt1, 5=-CAAACTTT GCTTTCCCTGGT-3= (forward) and 5=-CAAGGGCATATCCAACA ACA-3= (reverse); mouse Gapdh, 5=-GGGCTCATGACCACAGTCCA TGC-3= (forward) and 5=-CCTTGCCCACAGCCTTGGCA-3= (reverse).
Statistical analysis. Averages, standard deviations (SD), and standard errors of the means (SEM) were calculated using Prism (GraphPad Software). Significance was calculated using an unpaired Student's t test. Results with P Ͻ 0.05 were considered statistically significant and are indicated with an asterisk in the figures. Additionally, the significance of the qRT-PCR results was calculated using the Wilcoxon-Mann-Whitney test for paired samples, and P Ͻ 0.05 was considered significant.
RESULTS
Expansion of the zone of hypertrophic chondrocytes in Adam17
؊/؊ mice. To assess the role of ADAM17 in endochondral ossification, we performed a whole-mount analysis of newborn Adam17 Ϫ/Ϫ mice. Inspection of alcian blue/alizarin red-stained skeletons revealed an expansion of the blue staining for cartilage at the COJ in the developing scapula (Fig. 1a, arrows) and at other epiphyseal plates, although the skeletons of Adam17 Ϫ/Ϫ mice were otherwise very similar to that of wt controls. The expanded area of blue staining at the COJ prompted us to further explore how lack of ADAM17 affects the growth plate by performing a histological analysis of sections of the tibiae and humeri stained with H&E (Fig. 1b, top) or safranin O/fast green (Fig. 1b, lower) . This uncovered a significant enlargement of the zone of hypertrophic chondrocytes in the growth plates of the long bones of Adam17 Ϫ/Ϫ mice compared to controls. The average length of the hypertrophic zone of the proximal humerus in Adam17 Ϫ/Ϫ mice was about double that of controls (Fig. 1c) . We next analyzed sections of Adam17 Ϫ/Ϫ and control humeri at different stages of embryonic development (E14.5, E16.5, and E18.5). At E14.5, the zone of hypertrophic chondrocytes extended from one end of the growth plate to the other in Adam17 Ϫ/Ϫ humeri, with no evidence of a primary ossification center (POC), which clearly divided the growth plate of wt littermates into two parts at this stage (Fig. 1d) . By E16.5, the Adam17 Ϫ/Ϫ humeri had also developed a POC; however, the zone of hypertrophic cells was expanded compared to the zone of littermate controls (Fig. 1e) , and this phenotype remained evident at E18.5 (Fig. 1f) .
Expansion of the hypertrophic zone is caused by conditional deletion of Adam17 in chondrocytes but not in osteoclasts or endothelial cells. Since Adam17 Ϫ/Ϫ mice die at birth, we generated mice lacking ADAM17 in chondrocytes (Adam17 flox/flox /Col2a1-Cre [A17⌬Ch] mice; see Materials and Methods for details) to assess the role of ADAM17 in these cells during postnatal endochondral ossification. A17⌬Ch mice were born at the expected Mendelian ratio and were indistinguishable from their littermate controls (Adam17 flox/flox lacking Col2a1-Cre) upon visual inspection and during routine handling (for A17⌬Ch mice, n ϭ 87 [51%]; controls, n ϭ 82 [49%]; total n ϭ 169). Alizarin red/alcian blue-stained wholemount skeletons showed an enlarged hypertrophic zone in the scapulae of A17⌬Ch mice compared to controls (Fig. 2a, arrows) , similar to newborn Adam17 Ϫ/Ϫ mice (Fig. 1a) . Moreover, histological analysis revealed a significant expansion of the hypertrophic zone in the A17⌬Ch humeri relative to those of wt littermates (Fig. 2b and c) . No enlargement of the zone of hypertrophic cells was observed in mice expressing Col2a1-Cre with wt ADAM17 (data not shown). Several other cell types contribute to the formation of the growth plate in addition to chondrocytes, most prominently osteoclasts, endothelial cells, and osteoblasts. Since an enlarged growth plate could also be caused by a defect in osteoclast function, we analyzed the growth plates in mice lacking ADAM17 in myeloid cells (A17⌬MC), which give rise to osteoclasts and monocytes (41) . No significant difference in the size of the hypertrophic zone was evident in A17⌬MC mice compared to controls at birth (Fig. 2b and c) , even though ADAM17 is efficiently deleted from myeloid cells in these animals (41) . Additionally, Adam17 flox/flox animals carrying both LysM-Cre and Col2a1-Cre (A17⌬MC/Ch) to inactivate ADAM17 in the myeloid/osteoclast lineage and in chondrocytes had a zone of hypertrophic chondrocytes that was comparable to that of A17⌬Ch mice (Fig. 2b and c) . When we examined the growth plates of mice lacking ADAM17 in endothelial cells (A17⌬EC), we found no difference in the size of the hypertrophic zone compared to that of the controls (Fig. 2b and c) , despite efficient deletion of ADAM17 in endothelial cells (29) .
ADAM17 has been characterized as a principal sheddase for tumor necrosis factor alpha (TNF-␣) and for several EGFR ligands (12, 15, (42) (43) (44) . As noted in the introduction, previous studies have established a role for the EGFR and its ligand, TGF␣, in endochondral ossification, but little is known about the role of TNF-␣ in this process. Therefore, we analyzed the growth plate of Tnf␣ Ϫ/Ϫ mice (45) but found no significant difference in the total size of the hypertrophic zone or the relative distribution of the different cell types compared to controls (Fig. 2b and c) .
Western blot analysis of extracts of freshly isolated microdissected growth plates from humeri, femora, and tibiae of A17⌬Ch mice (P2) confirmed a significant reduction in ADAM17 (Fig. 2d and e), along with a significant reduction in staining for the phosphorylated EGFR levels ( Fig. 2d and e) . ADAM9 served as a loading control.
Growth defect in long bones of A17⌬Ch mice. To learn more about postnatal endochondral ossification in A17⌬Ch mice, we performed a histopathological analysis of the proximal humerus growth plate at P7, P14, and P21 and of the proximal tibia at P21 and in 20-week-old adults. The expanded zone of hypertrophic cells in the A17⌬Ch humeri was clearly apparent at P7 and P14 but was comparable to that of controls at P21 (Fig. 3a) . Tibiae from P21 A17⌬Ch mice showed a significant expansion of the hypertrophic zone compared to controls (Fig. 3b) , whereas the hypertrophic zone in the tibiae of 20-week-old A17⌬Ch mice were indistinguishable from littermate controls (Fig. 3b) . The growth plate and secondary ossification center of A17⌬MC, A17⌬EC, and Tnf␣ Ϫ/Ϫ mice also appeared normal at P21 (data not shown). When we measured the length of bones at different stages of development, we found that the long bones of A17⌬Ch mice were significantly shorter than those of control mice starting at P14 and P21. The femora and tibiae of A17⌬Ch adults (20 weeks old) were 5% shorter than those of littermate controls ( Fig. 3c and d) . However, there was no significant difference in the total weight of A17⌬Ch mice compared to controls at any stage of development (data not shown).
Calcified cartilage within the growth plate is expanded in A17⌬Ch mice. To learn more about how ADAM17 in chondrocytes affects mineralization, tibiae from P21 A17⌬Ch male mice and wt controls were analyzed by CT imaging. No difference was noted in the trabecular or cortical bone between A17⌬Ch and wt animals ( Fig. 4a to c) . Analysis of the calcified cartilage and the growth plate, defined as the space between the primary and secondary ossification centers, demonstrated that the expanded part of the hypertrophic zone is composed of calcified cartilage, whereas the nonmineralized parts of the growth plate were comparable in size between A17⌬Ch mice and controls ( Fig. 4d  and e) . In addition, the bone volume fraction (i.e., bone volume/total volume) was increased in the growth plates of A17⌬Ch mice relative to controls (Fig. 4d) . These findings were corroborated by a histological analysis of nondecalcified tissues, which revealed that the expanded area of hypertrophic chondrocytes in the growth plate of P0.5 Adam17 Ϫ/Ϫ (Fig.  4f) and A17⌬Ch (Fig. 4g) mice was positive for von Kossa staining, demonstrating that it is composed of mineralized matrix.
To learn how lack of ADAM17 affects matrix composition, we performed a Fourier transform infrared spectroscopic imaging analysis. This analysis provides a chemical photograph of the composition of the tissue. The compositional parameters were not significantly different when Adam17 Ϫ/Ϫ mice were compared to the wt, but the FTIR images showed that the mutant bones had an abnormal epiphyseal composition, with mineral that appeared to extend further into the zone of hypertrophic cells in the growth plate (Fig. 4 h and i) .
Evaluation of chondrocyte proliferation and apoptosis in Adam17
؊/؊ growth plates. The increased number of hypertrophic chondrocytes in Adam17 Ϫ/Ϫ mice could be caused by decreased apoptosis or increased proliferation. TUNEL staining at the COJ was comparable in Adam17 Ϫ/Ϫ growth plates and controls ( Fig. 5a and b) , suggesting that decreased apoptosis is not the cause for the increased cell numbers. The strongest TUNEL staining was observed in the cortical bone adjacent to the hypertrophic chondrocytes in both wild-type and Adam17 Ϫ/Ϫ growth plates. This zone was expanded in Adam17 Ϫ/Ϫ bones, most likely because of the expanded zone of hypertrophic cells. In addition, we found no difference in metabolic labeling with the nucleotide 5-ethynyl-2=-deoxyuridine (EdU) in chondrocytes in all zones of the growth plate between Adam17 Ϫ/Ϫ mice and controls ( Fig. 5c and d) . Together, these results indicate that the expanded hypertrophic zone in Adam17 Ϫ/Ϫ growth plates is not caused by changes in chondrocyte proliferation or apoptosis.
Analysis of the recruitment of osteoclasts, endothelial cells, and osteoblasts to the COJ. Multinucleated osteoclasts migrate into the COJ, where they aid in the selective digestion of the chondrocyte-generated extracellular matrix in order to allow the synthesis of bone matrix by osteoblasts (46) . Therefore, impaired osteoclastogenesis can lead to expanded hypertrophic zones in mice. When we assessed the number and location of osteoclasts in tibiae of newborn mice by tartrate-resistant acid phosphatase (TRAP) staining, we found no difference in the number of TRAPpositive cells at the COJ in Adam17 Ϫ/Ϫ or A17⌬Ch mice compared to those of their littermate controls, suggesting that ADAM17 is not required for recruitment of osteoclasts to the COJ at P0.5 ( Fig. 6a and b) . However, examination of P21 tibiae showed a significant reduction in TRAP-positive osteoclasts at the COJ in A17⌬Ch mice relative to controls ( Fig. 6c and d) . Nevertheless, there was no significant difference in the concentration of collagen crosslaps in the serum (serum CTX) of A17⌬Ch mice compared to controls, suggesting that overall osteoclast activity is comparable (Fig. 6e) . Moreover, no significant difference in endomucin staining, which allows visualization of endothelial cells in bone (47) , was observed at the COJ of Adam17 Ϫ/Ϫ mice at P0.5 or in A17⌬Ch mice at P21 compared to littermate controls, suggesting that the expanded hypertrophic zone is not caused by an inability to recruit endothelial cells to the COJ (Fig. 6f to i) . Finally, there was no difference in osteoblast morphology, number, distribution, or location relative to trabeculae in the growth plate of newborn Adam17 Ϫ/Ϫ mice or of A17⌬Ch mice at P21 compared to their controls (data not shown).
Chondrocyte-specific molecular signatures suggest that ADAM17 regulates terminal differentiation of chondrocytes. To further characterize the differentiation status of the chondrocytes in the enlarged hypertrophic zone of P0.5 Adam17 Ϫ/Ϫ mice, we performed in situ hybridization analysis for Col2a1 mRNA to visualize proliferating chondrocytes (Fig. 7a) , Col10a1 and Mmp13 mRNA to define the zone of hypertrophic cells (Fig. 7b  and c) , and Runx2 as a marker for hypertrophic chondrocytes and osteoblasts (Fig. 7d) . Col2a1 mRNA levels were comparable in Adam17 Ϫ/Ϫ and wt mice, suggesting that the lack of ADAM17 does not affect the distribution of proliferating chondrocytes. However, the zone of Col10a1-expressing cells was strongly expanded in Adam17 Ϫ/Ϫ mice, providing additional evidence that the terminally differentiated chondrocytes are most strongly affected by the lack of ADAM17. The analysis of Mmp13 mRNA indicated that its expression pattern adjacent to the hypertrophic chondrocytes at the COJ was similar in wt and Adam17 Ϫ/Ϫ mice, although the Mmp13 expression appeared to be increased in chondrocytes closer to the cortical bone in Adam17 Ϫ/Ϫ mice. Finally, the mRNA levels of the osteoblast marker Runx2 were comparable in Adam17 Ϫ/Ϫ and wt bones. To assess whether the lack of ADAM17 correlates with defective processing of type II collagen, the main structural component of cartilage, we performed immunohistochemical analysis of growth plates with an antibody against a type II collagen cleavage neo-epitope (C1,2C), which provides a readout for the processing of type II collagen. In wt growth plates, C1,C2-positive immunostaining was seen in hypertrophic chondrocytes, with the exception of the final layer of these cells immediately adjacent to the COJ. In Adam17 Ϫ/Ϫ growth plates, there was only a thin layer of C1,C2-positive cells adjacent to the zone of proliferating chondrocytes, whereas the expanded zone of hypertrophic cells was C1,C2 negative (Fig. 7e) .
Enhanced in vitro differentiation of hypertrophic chondrocytes lacking ADAM17. To understand if the role of ADAM17 in the growth plate is cell type specific for chondrocytes, we examined how the loss of ADAM17 affects in vitro differentiation of murine primary chondrocytes to the terminal hypertrophic state using two different systems of in vitro hypertrophic differentiation: monolayer and pellet cultures. We first evaluated the differentiation of monolayer cultures from wt and Adam17 Ϫ/Ϫ chondrocytes by alizarin red staining and by qRT-PCR analysis of Col10a1, Runx2, Vegfa, Mmp13, RankL, and Opg mRNA expres- sion. Chondrocytes lacking ADAM17 displayed enhanced hypertrophic differentiation in vitro, as evidenced by the increased number of alizarin red-stained nodules after 4 weeks of differentiation, which could be completely prevented by adding soluble TGF␣ to knockout and wt cells (Fig. 8a and b) . In addition, we found significantly increased Col10a1 and Runx2 levels after 3 weeks of differentiation ( Fig. 8c and d) and significantly increased Vegfa expression after 4 weeks of differentiation (Fig. 8e) in the Adam17 Ϫ/Ϫ chondrocytes compared to wt controls. Interestingly, Mmp13 and Opg expression levels were not significantly changed in Adam17 Ϫ/Ϫ chondrocyte cultures relative to controls, whereas RankL levels were significantly decreased (Fig. 8f to h) . Similarly, experiments performed in pellet cultures, which allow the cells to grow in a three-dimensional matrix (48; also see Materials and Methods for details), further confirmed that Col10a1, Runx2, Vegfa, and Ihh mRNA levels were significantly higher in 3-weekold Adam17 Ϫ/Ϫ cultures than in wt controls (Fig. 8i to l) . There was no difference in the expression of Hes/Hey, used as readouts for Notch signaling, or of Mmp9 or parathyroid hormone-related protein (Pthrp) (data not shown). The phosphorylation of SMAD1/5/8 was comparable in both wt and Adam17 Ϫ/Ϫ chondrocytes (data not shown).
ADAM17 is the principal sheddase for TGF␣ and HB-EGF in primary chondrocytes. Chondrocyte pellet cultures form a cartilage-like matrix over time; therefore, they provide an opportunity to assess the expression of EGFR ligands that are substrates for ADAM17 (HB-EGF, TGF␣, amphiregulin, epiregulin, and epigen) or ADAM10 (EGF) in a more physiological system. Realtime PCR analysis of RNA isolated from 3-week-old pellet cultures revealed that HB-EGF expression (Fig. 9a ) was higher than that of TGF␣ and EGF (Fig. 9b) , whereas amphiregulin and epigen expression was not detectable under the conditions utilized in this study (data not shown). There was no difference in EGFR ligand expression between the Adam17 Ϫ/Ϫ and wt pellets ( Fig. 9a and b) . We then attempted to detect shedding of endogenous TGF␣ or HB-EGF in the conditioned medium of wt and Adam17 Ϫ/Ϫ pellet cultures after 3 weeks, but we found that the sensitivity of the enzyme-linked immunosorbent assays for these EGFR ligands was not sufficient for this purpose. Therefore, we monitored the release of transfected alkaline phosphatase-tagged TGF␣, HB-EGF, or EGF into the supernatants of primary chondrocytes. The shedding of TGF␣ and HB-EGF from Adam17 Ϫ/Ϫ chondrocytes was significantly reduced compared to that of wt controls, whereas the release of the ADAM10 substrate EGF was not affected (Fig. 9c) .
DISCUSSION
This study identified a critical role for ADAM17 in hypertrophic chondrocytes during endochondral ossification. The finding that Adam17 Ϫ/Ϫ mice have an enlarged zone of hypertrophic chondrocytes could be recapitulated here by selective inactivation of Adam17 in chondrocytes but not by removing it from endothelial cells or osteoclasts. In mice lacking ADAM17 in chondrocytes, we observed an expansion of the most terminally differentiated type of mineralizing hypertrophic chondrocytes in the zone of provisional calcification, which normally occupies the area immediately adjacent to the COJ. This presumably resulted in improper remodeling of the mineralized matrix surrounding chondrocytes at the COJ and ultimately led to retarded growth of long bones.
The first part of this study focused on the characterization of bone development and endochondral ossification at different stages of embryogenesis in Adam17 Ϫ/Ϫ mice up to the time of their perinatal lethality. Morphological abnormalities in the growth plate of Adam17 Ϫ/Ϫ embryos could first be detected at E14.5, when humeri from Adam17 Ϫ/Ϫ mice were filled with hypertrophic chondrocytes, with no evidence for the development of a primary ossification center (POC). A similar delay in the initia- Ϫ/Ϫ humeri with antibodies against the collagen II 1C,2C neoepitope, which is generated through processing by collagenases. Scale bar, 100 m.
tion of the POC has been reported in Egfr Ϫ/Ϫ mice (30) . Nevertheless, a primary center of ossification develops with some delay in Adam17 Ϫ/Ϫ bones, suggesting that these defects eventually can be overcome. At subsequent stages of bone development, Adam17 Ϫ/Ϫ mice display an enlarged zone of hypertrophic cells, which is also clearly evident at birth.
To identify which cell types are the most important for the function of ADAM17 in the development of the pre-and postnatal growth plate, we conditionally inactivated Adam17 in chondrocytes (Col2a1-cre/A17⌬Ch), in myeloid cells and osteoclasts (LysM-cre/A17⌬MC), or in endothelial cells (Tie2-Cre/A17⌬EC). We found that the zone of hypertrophic cells was strongly enlarged following inactivation of ADAM17 in chondrocytes but not when it was removed from endothelial cells or osteoclasts, highlighting that chondrocytes are most likely the cell type that requires ADAM17 during endochondral ossification. Previous studies have shown that the deletion of ADAM17 is very efficient in endothelial cells or myeloid cells using the same conditional knockout strains (28, 29) , so the absence of a bone phenotype in A17⌬MC or A17⌬EC animals argues against a critical role for ADAM17 in these cell types in the growth plate. Additionally, we did not see any difference in the growth plates of Tnf␣ Ϫ/Ϫ mice compared to those of littermate controls, suggesting that the mechanism underlying the role of ADAM17 in bone growth does not depend on the shedding of TNF-␣, which is a major function of ADAM17 (28, 42, 43) . Finally, we did not observe any evident defects in osteoblasts in the growth plate of Adam17 Ϫ/Ϫ mice, and osteoblasts cultured from A17⌬Ch mice had normal levels of ADAM17 and developed normally, at least as measured by alkaline phosphatase production (data not shown). Although these experiments cannot rule out a contribution of ADAM17 in osteoblasts to the growth plate phenotype of A17⌬Ch mice, they support the conclusion that the enlarged zone of hypertrophic cells is caused by the lack of a function of ADAM17 in chondrocytes.
Mice lacking TGF␣, rats treated with the EGFR-inhibitor gefitinib, or mice carrying a mutant form of the EGFR or lacking the EGFR in chondrocytes all show similar increases in the zone of hypertrophic cells of the growth plate (8, 23, 49, 50) . These studies are consistent with the notion that the abnormalities in endochondral ossification in A17⌬Ch mice are caused by a defect in activation of the EGFR by the ADAM17 substrate and EGFR ligand TGF␣. This model is further supported by our findings that TGF␣ and the ADAM17 substrate HB-EGF are expressed in chondrocytes, and that there is a defect in the proteolytic release of these two EGFR-ligands from Adam17-deficient chondrocytes.
Further histopathological evaluation showed that the loss of ADAM17 mainly affected a specialized subset of cells in the growth plate of mutant mice, the mineralizing hypertrophic chondrocytes. In newborn mice, the expanded layer of hypertrophic chondrocytes showed reduced staining with an antibody that detects collagen cleavage sites generated by collagenases such as MMP13. Moreover, the mineralized matrix surrounding hypertrophic chondrocytes extended much further into the zone of hypertrophic cells in Adam17 Ϫ/Ϫ and A17⌬Ch mice than in wt controls and appeared to encompass the entire expanded region in these animals. Only the most distal row of terminally differentiated hypertrophic chondrocytes is usually mineralized in wt animals, which suggests that the chondrocytes in the enlarged hypertrophic zone in Adam17 Ϫ/Ϫ and A17⌬Ch mice represent additional layers of the most terminally differentiated mineralizing hypertrophic chondrocytes. These observations were confirmed by CT analysis of young adult animals at P21. Overall, the three-dimensional volume of the growth plate tissue, which includes all nonmineralized chondrocytes (resting, proliferating, and majority hypertrophic) but excludes the mineralizing hypertrophic cells, was not significantly different between wt and A17⌬Ch mice. However, the volume of the area of calcified cartilage was almost doubled in A17⌬Ch mice and had an increased density of signal per area, demonstrating increased mineralization in knockouts compared to wt controls. FTIR analysis demonstrated that the composition of the mineral of the trabecular bone was comparable between A17⌬Ch and wt mice, although the distribution of the mineral around hypertrophic cells appeared to differ. Interestingly, there was no augmented mineralization in the enlarged zone of hypertrophic cells in the growth plate in gefitinib-treated rats (7) . This finding could be explained by speciesspecific differences in the role of the EGFR in matrix mineralization in the zone of hypertrophic chondrocytes, although it is also possible that pharmacological inhibition does not completely recapitulate the consequences of genetic inactivation of this pathway. The hypothesis that ADAM17 regulates the mineralization of hypertrophic chondrocytes by activating the EGFR in chondrocytes is further supported by a study demonstrating that Egfr⌬Ch mice have an enlarged zone of hypertrophic chondrocytes that resembles that observed in A17⌬Ch mice (49) .
There could be several explanations for the increased size of the layer of mineralizing hypertrophic chondrocytes in the absence of ADAM17, including increased proliferation or decreased apoptosis. However, we found no evidence for either mechanism, suggesting that ADAM17-deficient hypertrophic chondrocytes either synthesize more mineralizable matrix or are unable to remodel the mineralizing matrix to allow vascularization. The comparable number and spacing of TRAP-positive osteoclasts adjacent to the COJ in newborn Adam17 Ϫ/Ϫ mice and wt controls, together with a similar distribution and spacing of endothelial cells and osteoblasts, argues against a major defect in the recruitment of these three cell types to the COJ when ADAM17 is lost at this stage. Nevertheless, we cannot unequivocally rule out an impairment of the function of the endothelial cells, osteoclasts, or osteoblasts at the COJ. In young adult A17⌬Ch mice, there was a reduction in the number of osteoclasts at the COJ, which is consistent with the reduced expression of RANKL and increased OPG production after long-term culture of Adam17 Ϫ/Ϫ chondrocytes, as also described by Saito et al. (49) . However, the resulting reduction in osteoclast recruitment most likely was not the primary cause of the increased size of the zone of hypertrophic cells, as this was already clearly present at P0.5, when the number of osteoclasts at the COJ appeared normal in mutant mice. The finding of similar levels of serum crosslaps in A17⌬Ch mice compared to controls suggests that overall osteoclast activity was not significantly affected by the loss of ADAM17 in chondrocytes.
The increase in alizarin red-stained nodules in long-term cultures of isolated Adam17 Ϫ/Ϫ chondrocytes is an indicator of enhanced hypertrophic differentiation (51) and suggests that the defect is chondrocyte specific. This hypothesis is further supported by the increase in the expression of Col10a1, Runx2, and Vegfa in monolayer culture and in 3-dimensional cultures of Adam17 Ϫ/Ϫ chondrocytes compared to controls. The increased in vitro differentiation was blocked by addition of soluble TGF␣ to both wt and knockout primary chondrocytes, demonstrating that gain-of-function experiments (adding the soluble cleavage product that is released by ADAM17) have the opposite effect of lossof-function experiments (inactivation of the TGF␣ sheddase ADAM17). The comparable expression of Hes/Hey, indicators of Notch signaling, and similar phosphorylation of Smad1/5/8, used to monitor BMP signaling, argue against a role for ADAM17 in Notch or BMP signaling in chondrocytes.
Taken together, these results are consistent with a model in which a chondrocyte-specific defect in Adam17 Ϫ/Ϫ mineralizing hypertrophic chondrocytes affects the remodeling of the calcified matrix surrounding the final layers of hypertrophic chondrocytes, most likely because of a lack of TGF␣/EGFR signaling and reduced production of matrix-remodeling collagenases. Thus, the main role of ADAM17 in endochondral ossification apparently is to control the function of the most terminally differentiated hypertrophic chondrocytes in the growth plate. Since the enlarged zone of hypertrophic chondrocytes in the growth plate of A17⌬Ch mice resembles that of Tgf␣ Ϫ/Ϫ mice and of mice and rats with genetic or pharmacological inhibition of EGFR signaling, ADAM17 most likely functions as an upstream regulator of EGFR signaling by controlling the release of TGF␣, one of its principal substrates, from hypertrophic chondrocytes. In the absence of ADAM17, the most terminally differentiated mineralizing hypertrophic chondrocytes accumulate, giving rise to an enlarged calcified zone of hypertrophic cells. At later stages of development, this phenotype is presumably further exacerbated by decreased recruitment of osteoclasts to the COJ. The result is retardation in long bone growth, most likely caused by delayed or defective remodeling of the growth plate. It is worth noting that several types of EGFR inhibitors are already approved for treatment of cancer, and ADAM17 is considered a good target for treatment of EGFR-and TNF-␣-dependent pathologies. Therefore, the finding that AD-AM17/EGFR signaling affects the function of chondrocytes and, thus, bone and cartilage homeostasis raises interesting questions regarding the possible indication or contraindication of these treatments in the context of degenerative joint diseases, such as osteoarthritis and rheumatoid arthritis. 
